Accubiotech Inc

Silver Lake Research Corp, based in Irwindale, CA, has been a pioneer in the development, manufacturing, and marketing of novel diagnostics since 1992. The company specializes in rapid point-of-care test kits that utilize EAP-derived monoclonal antibodies, offering unmatched accuracy and sensitivity that meet or exceed laboratory standards. With a commitment to innovation, Silver Lake Research produces customized immunoassays and operates one of the largest independent automated production facilities for lateral flow tests in the USA. Their product lineup includes HemoTypeSC, a test for hemoglobin phenotypes, and RapidBac, a quick urine culture alternative, reflecting their dedication to providing effective diagnostic solutions. Generated from the website

Biofriendly Corp is a California-based company that offers a range of eco-friendly products and solutions. They accept returns within 30 days of purchase for unopened items in their original packaging, and provide refunds for regular-priced items. Additionally, they offer exchanges for defective or damaged goods. With a commitment to sustainability, Biofriendly Corp prioritizes the well-being of the planet by promoting environmentally friendly practices. Customers can rely on their high-quality products and services, as well as their dedication to reducing the carbon footprint and creating a greener future.Generated from the website

GeneFluidics, based in Duarte, CA, is a pioneering company that was established in 2000 with the aim of developing a cutting-edge testing system to enhance global health. By combining innovative bionano and microfluidic technologies, their revolutionary platform allows for complex tests that are typically conducted in laboratories by skilled technicians to be performed by anyone, anywhere. With a simple process that involves introducing a raw sample into a disposable cartridge and waiting for the results, GeneFluidics' platform offers fast, accurate, and user-friendly testing solutions. With a focus on nanotechnology-enabled analyte detection and microfluidic-based automated sample preparation, GeneFluidics' platform was initially conceived as part of a biodefense program. Over the years, the company has achieved significant milestones, including being selected as a finalist for the Antimicrobial Resistance Diagnostic (AMR) Challenge Step 2 and obtaining CE-IVD marking for their UtiMax uropathogen identification and antimicrobial susceptibility testing (AST). Additionally, GeneFluidics has received funding from the National Institute of Allergy and Infectious Diseases (NIAID) for the development and clinical validation of diagnostics, further solidifying their position as a leader in the field.Generated from the website